Sangamo Therapeutics (SGMO) said Thursday it signed a license agreement with Eli Lilly (LLY) to use its STAC-BBB adeno-associated virus capsid for diseases of the central nervous system.
The deal grants Lilly worldwide rights to use the STAC-BBB capsid for one initial target, with the option to add up to four more.
Sangamo said it will get an $18 million upfront license fee and may receive up to $1.4 billion in additional licensed target fees and milestone payments for the five potential disease targets, in addition to royalties on potential sales.
The shares of Sangamo Therapeutics were rising past 26% in after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。